Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain

Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain

Josep M Llibre,1,2 Gloria Cardona,3 José R Santos,2 Angels Andreu,3 Josep O Estrada,4 Jordi Ara,4 Xavier Bonafont,3 Bonaventura Clotet1,21HIV Unit, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; 2Lluita contra la SIDA Foundation, Badalona, Barcelona, Spain; 3Hospit...

Full description

Bibliographic Details
Main Authors:	Llibre JM, Cardona G, Santos JR, Andreu A, Estrada JO, Ara J, Bonafont X, Clotet B
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-05-01
Series:	ClinicoEconomics and Outcomes Research
Online Access:	http://www.dovepress.com/antiretroviral-treatment-switch-strategies-for-lowering-the-costs-of-a-a13125

Similar Items

Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging
by: Andreu-Crespo À, et al.
Published: (2015-08-01)

Persistent HIV-1 Viremia on Antiretroviral Therapy: Measurement and Mechanisms
by: Jana L. Jacobs, et al.
Published: (2019-10-01)

Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy
by: Leonardo Weissmann, et al.
Published: (2019-11-01)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
by: Josep M Llibre, et al.
Published: (2015-01-01)

Association between time spent with residual viremia after achievement of virological suppression and type of first-line antiretroviral regimen
by: A. Lazzarin, et al.
Published: (2017-12-01)

Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy.
by: Anthony R Cillo, et al.
Published: (2014-01-01)

Relationship between adherence to antiretroviral therapy and the cost-effectiveness of antiretroviral therapy and the patterns of antiretroviral regimen switches
by: Habib, Mohdhar Jeilan, 1971-
Published: (2008)

Switch & simplification of antiretroviral therapy
by: Waters, Laura Jane
Published: (2013)

Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans
by: Azwidowi Lukhwareni, et al.
Published: (2020-06-01)

HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
by: Daniela Souza Araújo de Angelis, et al.

Low-Level Viremia Predicts Virological Failure in HIV-Infected Omani Patients Receiving Antiretroviral Therapy
by: Zied Gaifer MBBS, MD, et al.
Published: (2020-12-01)

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.
by: Constance Delaugerre, et al.
Published: (2012-01-01)

HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy
by: Daniela Souza Araújo de Angelis, et al.
Published: (2011-01-01)

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
by: Maud Mavigner, et al.
Published: (2009-10-01)

Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
by: Olof Elvstam, et al.
Published: (2017-01-01)

Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
by: Alain Amstutz, et al.
Published: (2020-09-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy.
by: Nicole E Behrens, et al.
Published: (2020-01-01)

Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy
by: Nicole E. Behrens, et al.
Published: (2020-01-01)

Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection.
by: Anders Boyd, et al.
Published: (2014-01-01)

A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.
by: Panagiotis Vagenas, et al.
Published: (2010-09-01)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
by: Sandberg Johan K, et al.
Published: (2011-06-01)

Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
by: Rajesh T Gandhi, et al.
Published: (2010-08-01)

Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.
by: Alexander O Pasternak, et al.
Published: (2009-12-01)

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
by: Nancie M Archin, et al.
Published: (2010-02-01)

Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa.
by: Katherine Fielding, et al.
Published: (2011-01-01)

Investigating the risk factors associated with low-level viremia and virological failure in HIV-1 infected children undergoing antiretroviral therapy
by: Gupta, Shivani
Published: (2017)

Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy
by: Mehwish Younas, et al.
Published: (2021-03-01)

Influence of provider experience on antiretroviral adherence and viral suppression
by: Horberg MA, et al.
Published: (2012-08-01)

Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial.
by: Rajesh T. Gandhi, et al.
Published: (2011-08-01)

Herpes Zoster in Persons Living with HIV-1 Infection: Viremia and Immunological Defects Are Strong Risk Factors in the Era of Combination Antiretroviral Therapy
by: Nathaniel B. Erdmann, et al.
Published: (2018-03-01)

Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
by: Guan-Jhou Chen, et al.
Published: (2021-04-01)

Evidence of ongoing HIV replication during suppressive antiretroviral therapy
by: L. Bertoni Giron, et al.
Published: (2015-12-01)

Possible role of plasma Galectin-9 levels as a surrogate marker of viremia in HIV infected patients on antiretroviral therapy in resource-limited settings
by: Ashwini Shete, et al.
Published: (2020-07-01)

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
by: José R Santos, et al.
Published: (2012-01-01)

New antiretrovirals
by: Gulick Roy
Published: (2012-05-01)

Five Antiretroviral Drug Class–Resistant HIV-1 in a Treatment-Naïve Patient Successfully Suppressed with Optimized Antiretroviral Drug Selection
by: Joseph M. Volpe PhD, et al.
Published: (2015-09-01)

The ethics of switch/simplify in antiretroviral trials: non-inferior or just inferior?
by: Andrew Carr, et al.
Published: (2012-01-01)

Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort
by: Tong Zhang, et al.
Published: (2020-02-01)

Cannot write session to /tmp/vufind_sessions/sess_icsup7cl8f4oik6es027ea434d